Skip to content

Applied Nutrition Profit Growth Trails 51% Sales Rise

Applied Nutrition's sales rose 51% in the year to July, but profit grew more slowly as gross margin fell and cash conversion dropped. The company has guided to a slightly lower EBITDA margin again in FY27.

Applied Nutrition (LON: APN) reported a 50.9% rise in full-year revenue to £161.6m, but profit grew more slowly. The Liverpool-based sports nutrition brand sells mainly to other businesses in over 90 countries.

The shares traded at 299.9p at 08:37 UK time today, down 4.9% from Friday’s close of 315.5p. The day’s range so far runs from 292.5p to 310p.

APN.LSE

Growth came from every region, the results statement said: UK sales rose 45.2%, Europe 34.0% and Rest of World 63.3%. Forty-eight of the top 50 business customers grew, UK grocers’ sales rose 180%, and the relaunched Critical Whey range grew 142%. Acquired US manufacturer Nutrablend added £1.6m.

Profit lagged sales. Adjusted EBITDA, profit before interest, tax, depreciation and one-offs, rose 40.1% to £43.3m. Gross margin, the share of sales left after direct costs, fell 190bps (hundredths of a percentage point) to 44.1% on staff costs and temporary off-site storage.

Line chart of Applied Nutrition revenue and adjusted EBITDA for FY25 and FY26 showing revenue rising more steeply
Applied Nutrition revenue grew faster than adjusted EBITDA in the year to 31 July 2026. Source: company results

In our calculation from the reported figures, adjusted EBITDA margin slipped to 26.8% from 28.9%. Cash fell back further:

MeasureFY26FY25Change
Revenue (£m)161.6107.1+50.9%
Gross margin44.1%46.0%-190bps
Adjusted EBITDA (£m)43.330.9+40.1%
Free cash flow (£m)10.616.5-35.8%

Free cash flow conversion, the share of adjusted profit turned into free cash, was 33.5% against 72.4%, as stock built up. Net cash was £15.9m after the roughly £12m Nutrablend purchase, and no dividend is expected before FY28.

Chief Executive Officer Thomas Ryder said the group entered FY27 with very strong momentum, yet the Board is holding expectations of adjusted EBITDA of about £49m and revenue of about £205m. On margins, he said:

we have planned for FY27 EBITDA margin to decrease slightly from FY26 levels.

Thomas Ryder, Chief Executive Officer, Applied Nutrition

The company cited more lower-margin US white-label sales, products made for other brands, and higher whey protein costs, partly offset by customer price increases. It described the results as in line with upgraded expectations, after two upgrades during the year.

Asktraders News Team
Asktraders News Team
Team Member

The AskTraders Analyst Team features experts in technical and fundamental analysis, as well as traders specializing in stocks, forex, and cryptocurrency.

Stay ahead of the markets

Sign up to our free Morning Markets email, every weekday before the open.